DA Davidson Issues Positive Forecast for Prestige Consumer Healthcare (NYSE:PBH) Stock Price

Prestige Consumer Healthcare (NYSE:PBH) had its price target raised by DA Davidson from $95.00 to $104.00 in a report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities research analysts also recently commented on PBH. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a report on Monday, December 9th. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Finally, StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and a consensus price target of $92.50.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $86.96 on Friday. Prestige Consumer Healthcare has a 12-month low of $60.00 and a 12-month high of $88.36. The stock has a market capitalization of $4.30 billion, a P/E ratio of 20.37, a P/E/G ratio of 2.43 and a beta of 0.50. The firm’s 50 day moving average is $79.19 and its 200-day moving average is $75.34. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Equities research analysts anticipate that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Mary Beth Fritz sold 9,885 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total transaction of $810,273.45. Following the transaction, the senior vice president now directly owns 18,835 shares of the company’s stock, valued at approximately $1,543,904.95. The trade was a 34.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider William P’pool sold 8,987 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the completion of the transaction, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,810 shares of company stock valued at $3,187,300. Corporate insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently modified their holdings of PBH. Millennium Management LLC boosted its position in Prestige Consumer Healthcare by 565.1% during the second quarter. Millennium Management LLC now owns 101,218 shares of the company’s stock valued at $6,969,000 after purchasing an additional 86,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of Prestige Consumer Healthcare by 562.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after purchasing an additional 433 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter valued at about $1,095,000. SG Americas Securities LLC bought a new stake in shares of Prestige Consumer Healthcare in the 3rd quarter valued at approximately $364,000. Finally, Handelsbanken Fonder AB increased its holdings in Prestige Consumer Healthcare by 8.2% in the third quarter. Handelsbanken Fonder AB now owns 14,481 shares of the company’s stock worth $1,044,000 after buying an additional 1,100 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.